A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2004
10/14/2004	US20040204481 Activation of natural killer cells by adenosine A3 receptor agonists
10/14/2004	US20040204477 For use as antiproliferative agents
10/14/2004	US20040204474 Hypotensive agents; cardiovascular disorders
10/14/2004	US20040204469 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
10/14/2004	US20040204467 Use of 5HT3-receptor-antagonists
10/14/2004	US20040204464 Isoxazoline compounds having MIF antagonist activity
10/14/2004	US20040204449 New isoquinoline compounds
10/14/2004	US20040204437 Substituted arylamine derivatives and methods of use
10/14/2004	US20040204436 Imidazonaphthyridines
10/14/2004	US20040204428 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments
10/14/2004	US20040204425 Sodium channel blockers
10/14/2004	US20040204418 For prophylaxis and therapy of asthma, chronic obstructive pulmonary disease, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilia, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease
10/14/2004	US20040204417 For therapy of cancer
10/14/2004	US20040204399 Aerosolized decongestants for the treatment of sinusitis
10/14/2004	US20040204393 Aromatase inhibition to enhance assisted reproduction
10/14/2004	US20040204369 Novel amide derivatives
10/14/2004	US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
10/14/2004	US20040204364 Peptides for activation and inhibition of deltaPKC
10/14/2004	US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages
10/14/2004	US20040204341 Nr2b receptor antagonists for the treatment or prevention of migraines
10/14/2004	US20040204338 Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action
10/14/2004	US20040203157 Transfroming arabidopsis with expression vector coding genes associated with heat, freeze, salt and drought resistance; using ribonucleoproteins to control effivient gene transcription in plants; bioreactors
10/14/2004	US20040203144 Using calcium-activated chloride channels (CLCA) to identify modulators for treatment of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and bronchiectasis
10/14/2004	US20040203128 Use of PP2A phosphatase modulators in the treatment of mental disorders
10/14/2004	US20040203124 Electrodes coated with treating agent and uses thereof
10/14/2004	US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene
10/14/2004	US20040203116 IL-1 eta DNA and polypeptides
10/14/2004	US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3
10/14/2004	US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents
10/14/2004	US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay
10/14/2004	US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling
10/14/2004	US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3
10/14/2004	US20040203087 screening gene expression inhibition via incubating mrna, determining expression in presence of test compound, then comparing levels; gene knockout
10/14/2004	US20040203054 Use of SLIM3 for binding to molecules
10/14/2004	US20040203014 Neurotransmisson-associated proteins
10/14/2004	US20040203003 comprising isolating messenger RNA and performing reverse transcription polymerase chain reaction (PCR) and assessing the concentrations of the resulting amplicons; genetic engineering
10/14/2004	US20040202734 Method for preparing nicotianamine or nicotianamine-containing product
10/14/2004	US20040202671 helminths obtained from preparatory animals raised in a specific human pathogen-free environment used to treat an excessive immune response including an aberrant/enhanced Th1 response, e.g., Crohn's disease and ulcerative colitis
10/14/2004	US20040202659 A polypeptide encoded by a nucleic acid that encodes a heavy chain, which is able to bind to GPIIb/IIIa, of a human antibody and comprising a CDR3 region; diagnosis, treatment or prevention of autoimmune thrombocytopenic purpura; modulating blood coagulation
10/14/2004	US20040202617 Delivery of opioids through an inhalation route
10/14/2004	US20040202616 comprises magnesium stearate for improved storage stability; inhalers
10/14/2004	DE10295684T9 Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 Method for the specific inhibition of histone deacetylase 4
10/14/2004	CA2518913A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
10/13/2004	EP1466975A1 Postsynaptic proteins
10/13/2004	EP1466913A1 Benzoylecgonine, ecgonine and ecgonidine derivatives
10/13/2004	EP1466912A1 2-acylaminothiazole derivative or salt thereof
10/13/2004	EP1466911A2 Preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
10/13/2004	EP1466904A1 Biaryl compound and use thereof
10/13/2004	EP1466902A1 Androgen receptor antagonists
10/13/2004	EP1466901A1 Serotonine reuptake inhibitor
10/13/2004	EP1466899A1 Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
10/13/2004	EP1466891A1 Carboxylic acid derivative
10/13/2004	EP1466889A1 Derivatives of venlafaxine and methods of preparing and using the same
10/13/2004	EP1466888A1 Calcium receptor-active arylalkyl amines
10/13/2004	EP1466626A1 Medicinal compositions for improving oral absorption
10/13/2004	EP1466625A1 Preventives/remedies for urinary disturbance
10/13/2004	EP1466624A1 Drug for regenerating tissue and vessel and method therefor
10/13/2004	EP1466615A1 Pharmaceutical composition
10/13/2004	EP1466614A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
10/13/2004	EP1466608A1 Herbal composition comprising Angelica gigantis, Cnidium officinale and Paeonia japonica
10/13/2004	EP1466606A2 Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
10/13/2004	EP1466605A2 Calcium channel blockers
10/13/2004	EP1466604A1 Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems
10/13/2004	EP1466602A1 Organ fibrosis inhibitors
10/13/2004	EP1466598A2 PDE-IV inhibitors
10/13/2004	EP1466175A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/13/2004	EP1466017A2 Tissue rejection
10/13/2004	EP1465997A2 Use of biomolecular targets in the treatment and visualization of tumors
10/13/2004	EP1465925A2 Antibodies that immunospecifically bind to trail receptors
10/13/2004	EP1465923A1 Corticotropin releasing factor receptor 2 agonists
10/13/2004	EP1465922A2 Corticotropin releasing factor receptor 2 agonists
10/13/2004	EP1465921A2 Corticotropin releasing factor receptor 2 agonists
10/13/2004	EP1465916A2 Novel g proein-coupled receptor, gave7
10/13/2004	EP1465901A2 Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
10/13/2004	EP1465900A1 Rho-kinase inhibitors
10/13/2004	EP1465895A2 4-oxo-4,7-dihydrofuro(2,3-b)pyridine-5-carboxamide antiviral agents
10/13/2004	EP1465891A2 Inhibitors of dipeptidyl peptidase iv
10/13/2004	EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
10/13/2004	EP1465888A2 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
10/13/2004	EP1465887A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
10/13/2004	EP1465886A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
10/13/2004	EP1465885A2 Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
10/13/2004	EP1465880A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
10/13/2004	EP1465872A1 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
10/13/2004	EP1465871A1 Pyrazole derivatives for use in diseases associated with the 5-ht2c receptor
10/13/2004	EP1465870A2 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
10/13/2004	EP1465869A1 Modulators of lxr
10/13/2004	EP1465868A1 Phenoxy piperidines for treating diseases such as schizophrenia and depression
10/13/2004	EP1465867A1 Ligands of melanocortin receptors and compositions and methods related thereto
10/13/2004	EP1465866A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
10/13/2004	EP1465863A1 Potassium channel modulators
10/13/2004	EP1465862A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
10/13/2004	EP1465861A1 Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
10/13/2004	EP1465854A2 Chalcone derivatives and their use to treat diseases
10/13/2004	EP1465852A1 Synthesis of combretastatin a-2 prodrugs
10/13/2004	EP1465662A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
10/13/2004	EP1465661A1 Cancer treatment
10/13/2004	EP1465660A2 Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
10/13/2004	EP1465654A2 Plasmid mediated suplementation for treating chronically ill subjects
10/13/2004	EP1465649A2 Methods and compositions for derepression of iap-inhibited caspase

1 ... 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 ... 1564